Lynda Cranston - Kintara Therapeutics Independent Director
Director
Ms. Lynda Sarah Cranston is Independent Director of the Company. She has served as a director since February 5, 2015. Mrs. Cranston comes to the Board with over 20 years of experience at the CEO level in healthcare. She is presently Chair of the British Columbia Rapid Transit Company. She previously was, from 2014 to 2016, the National Chair of the Gastrointestinal Association of Canada. In 2013 she retired from the healthcare industry and her last appointment prior to her retirement was as the first CEO of the British Columbia Provincial Health Services Authority . From 19982001, Mrs. Cranston had been the first CEO of the Canadian Blood Services in Ottawa, ON. Before moving to Ottawa, Mrs. Cranston, as the CEO of B.C. Womens Hospital and Healthcare Centre had merged the organization with the BC Childrens Hospital and the Sunny Hill Health Centre for Children to become the Childrens and Womens Healthcare Centre of BC. Following the merger Mrs. Cranston became the first CEO. In 2013, Mrs. Cranston was identified as a member of Diversity 50 by the Canadian Board Diversity Council as being one of Canadas most board ready candidates. Mrs. Cranston was awarded the Board Chair Award of Excellence by the HealthCare Leaders Association of British Columbia in 2008. In 2007, she was inducted into Canadas Most Powerful Women Top 100 Hall of Fame after having been identified in 04, 05 06 as one of Canadas Most Powerful Women Top 100. Mrs. Cranston is a recipient of the YWCA Women of Distinction Award, the 125th Anniversary of the Confederation of Canada Commemorative Medal for community contributions, and the Queens Golden Jubilee Medal for contribution to Canada and community. Mrs. Cranston is a graduate of the University of Ottawa and the University of Western Ontario. Mrs. Cranstons healthcare industry and executive knowledge and experience qualify her to serve on our Board of Directors. since 2015.
| Age | 69 |
| Tenure | 9 years |
| Phone | 858-350-4364 |
| Web | http://www.delmarpharma.com |
Kintara Therapeutics Management Efficiency
The company has return on total asset (ROA) of (136.86) % which means that it has lost $136.86 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (316.72) %, meaning that it created substantial loss on money invested by shareholders. Kintara Therapeutics' management efficiency ratios could be used to measure how well Kintara Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Matthew Peltz | The Wendys Co | 35 | |
| Sumaiya Balbale | Shake Shack | 39 | |
| Robert Vivian | Shake Shack | 61 | |
| Steven Johnson | Rave Restaurant Group | 56 | |
| Joshua Silverman | Shake Shack | 51 | |
| Peter Rothschild | The Wendys Co | 62 | |
| Dennis Kass | The Wendys Co | 67 | |
| Brian Bares | Rave Restaurant Group | 43 | |
| Peter Bassi | BJs Restaurants | 68 | |
| Wesley Nichols | BJs Restaurants | 51 | |
| Robert Page | Rave Restaurant Group | 58 | |
| Earl Webb | Pebblebrook Hotel Trust | 63 | |
| Janet Sherlock | BJs Restaurants | 52 | |
| Patrick Walsh | BJs Restaurants | 42 | |
| Jonathan Sokoloff | Shake Shack | 62 | |
| Tristan Walker | Shake Shack | 35 | |
| James Pozzo | BJs Restaurants | 59 | |
| Randolph Lewis | The Wendys Co | 64 | |
| Joseph Levato | The Wendys Co | 77 | |
| Rana Schirmer | BJs Restaurants | N/A | |
| Michelle MathewsSpradlin | The Wendys Co | 51 | |
Management Performance
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 |
Kintara Therapeutics Leadership Team
Elected by the shareholders, the Kintara Therapeutics' board of directors comprises two types of representatives: Kintara Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kintara. The board's role is to monitor Kintara Therapeutics' management team and ensure that shareholders' interests are well served. Kintara Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kintara Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Scott Praill, CFO and Principal Accounting Officer | ||
| John Bell, Independent Director | ||
| William Garner, Director | ||
| Erich Mohr, Independent Director | ||
| Saiid Zarrabian, Director | ||
| Robert Toth, Director | ||
| Dennis Brown, Chief Scientific Officer, Director | ||
| Jeffrey Bacha, President CEO, Director | ||
| Lynda Cranston, Independent Director | ||
| Robert Hoffman, Independent Director | ||
| Napoleone Ferrara, Director |
Kintara Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kintara Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -316.72 | |||
| Return On Asset | -136.86 | |||
| Current Valuation | 13.09 M | |||
| Shares Outstanding | 11.46 M | |||
| Shares Owned By Insiders | 1.44 % | |||
| Shares Owned By Institutions | 12.46 % | |||
| Number Of Shares Shorted | 246.63 K | |||
| Price To Earning | (1.68) X | |||
| Price To Book | 3.26 X | |||
| EBITDA | (8.26 M) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Kintara Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Kintara Therapeutics' short interest history, or implied volatility extrapolated from Kintara Therapeutics options trading.
Pair Trading with Kintara Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kintara Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kintara Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Parker Hannifin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Parker Hannifin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Parker Hannifin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Parker Hannifin to buy it.
The correlation of Parker Hannifin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Parker Hannifin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Parker Hannifin moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Parker Hannifin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Other Consideration for investing in Kintara Stock
If you are still planning to invest in Kintara Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kintara Therapeutics' history and understand the potential risks before investing.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |